Subcutaneous or intramuscular interferon-alpha (IFN-α) has been used in combination with intravenous chemotherapy for advanced HCC to enhance antitumor activity [55].
皮下或肌内干扰素(IFN-α)已与静脉化疗联合用于晚期HCC，以增强抗肿瘤活性[55]。
Subcutaneous IFN-α has also been combined with HAIC, resulting in higher ORRs than those achieved with HAIC alone, although the survival benefit of this combination is inconclusive [42,56,57].
However, a randomized Phase 2 trial comparing HAIC with or without IFN-α showed inferior OS for the group treated with the HAIC–IFN-α combination [43].
然而，一项比较HAIC联合或不联合IFN-α的随机2期临床试验显示，HAIC-IFN-α联合[43]治疗组的OS较低。
Because of such inconsistencies between study findings, IFN-α has not been routinely used in combination with HAIC.
由于研究结果之间的不一致，IFN-α还没有与HAIC常规联合使用。
|